Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MYBL2
REST API REST API
Homo sapiens
MYBL2 is differentially expressed in 284 experiments: 92 organism parts: bone marrow, blood, ... (90 more);, 171 disease states: normal, acute lymphoblastic leukemia, ... (169 more);, 94 cell types 313 cell lines 37 compound treatments and 77 other conditions.
Synonyms B-MYB, BMYB
Orthologs ENSCING00000002687 (Ciona intestinalis)   MYBL2 (Gallus gallus)   mybl2 (Danio rerio)   Mybl2 (Mus musculus)   BAS1 (Saccharomyces cerevisiae)   Q17QY0_BOVIN (Bos taurus)   Myb (Drosophila melanogaster)   Mybl2 (Rattus norvegicus)   myb (Danio rerio)   mybl2 (Xenopus laevis)   MYBL2 (Canis familiaris)   (Compare orthologs)
InterPro Term Myb_DNA-bd, SANT_DNA-bd, MYB-like, C-myb_C
Gene Ontology Term DNA binding, regulation of transcription, DNA-dependent, transcription, DNA-dependent, nucleus, sequence-specific DNA binding transcription factor activity
UniProt Accession P10244, F8W6N6
Search EB-eye ENSG00000101057
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-MEXP-433, E-GEOD-3526, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (33 experiments)

Factor Value U/D Experiments
BT474
3
E-MEXP-440, E-MTAB-62, E-MTAB-37
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
SW480
2
E-MEXP-1014, E-GEOD-18005
MDA-MB-231
2
E-TABM-420, E-MTAB-62
MOLT4
2
E-MTAB-62, E-MTAB-37
H820
1
E-MTAB-62
307 more value(s).


Cell type

studied in E-GEOD-500, E-GEOD-3920, E-GEOD-4219, E-GEOD-20677, E-GEOD-13987, ... (43 experiments)

Factor Value U/D Experiments
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
CD8+ T cell
2
E-AFMX-5, E-GEOD-19069
fibroblast
2
E-GEOD-3920, E-GEOD-3204
human embryonic stem cell
2
E-GEOD-20033, E-GEOD-18265
bone marrow CD34+ cell
1
E-GEOD-500
88 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-TABM-15, E-GEOD-16363, E-MTAB-62, ... (63 experiments)

Factor Value U/D Experiments
control
3
E-GEOD-16363, E-GEOD-20602, E-GEOD-3185
glioblastoma
3
E-GEOD-4290, E-MTAB-37, E-GEOD-4412
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
cervical carcinoma
2
E-MTAB-62, E-MEXP-1331
head and neck squamous cell carcinoma
2
E-GEOD-6631, E-GEOD-2379
lung adenocarcinoma
2
E-GEOD-2514, E-MTAB-62
165 more value(s).


Compound treatment

studied in E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-MEXP-2590, E-MEXP-1269, ... (26 experiments)

Factor Value U/D Experiments
ponasterone A
1
E-GEOD-3113
Cxcl12
1
E-GEOD-7307
vanadium pentoxide
1
E-GEOD-5339
TTA
1
E-MEXP-2590
AMP
1
E-MEXP-2285
CNOT7+CNOT8
1
E-MEXP-2218
31 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
not specified
1
E-GEOD-21521
LT6
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-2171, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (6 experiments)

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-3013 ... (5 experiments)

Environmental stress
studied in E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, E-MTAB-108, ... (7 experiments)

Genotype
studied in E-TABM-763, E-MEXP-1996, E-GEOD-3494, E-GEOD-17476, E-GEOD-18736, ... (8 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-20540, E-GEOD-20504, E-MEXP-1446, E-GEOD-9764, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-5764, E-GEOD-1926, E-GEOD-16363, ... (25 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-MEXP-561

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636, ... (8 experiments)

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-101, E-MEXP-548, E-GEOD-3697, E-MEXP-1857, E-MEXP-1315, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-4883, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, ... (9 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4290, E-GEOD-3494, E-TABM-43, E-GEOD-1561, ... (8 experiments)

Vehicle
studied in E-GEOD-5258

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.367 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM